MALMÖ, Sweden--(BUSINESS WIRE)--Regulatory News: Hansa Medical AB (publ) (STO:HMED) today announced that preliminary results of the Sweden based ongoing Phase II study of IdeS were presented today by ...
Good day, and welcome to the Hansa Biopharma Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Hansa Biopharma's CEO, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results